A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma. [electronic resource]
Producer: 20161213Description: 680-7 p. digitalISSN:- 1569-8041
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Carcinoma, Hepatocellular -- drug therapy
- Disease-Free Survival
- Double-Blind Method
- Female
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms -- drug therapy
- Male
- Middle Aged
- Niacinamide -- administration & dosage
- Phenylurea Compounds -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Sorafenib
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.